ArticleBriefings in bioinformatics2026
PGVDA: a pathway-aggregated genetic dosage framework for interpretable disease classification using machine learning.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Although neuromuscular junction disorders (NMDs) and inflammatory polyneuropathies (IPNs) are biologically distinct, direct genetic comparisons between them remain limited, suggesting that additional underlying biological differences may yet be uncovered. Few studies have explored whether differences in variant patterns within shared biological pathways can be leveraged to distinguish NMDs and IPNs using machine learning (ML). We propose an interpretable ML framework based on Pathway-based Genetic Variant Dosage Average (PGVDA) to classify NMDs and IPNs and to identify key genes and pathways differentiating diseases. Using nonsynonymous variants from 667 UK Biobank participants, logistic regression identified disease-associated variants. Significant pathways were identified via pathway enrichment analysis with adjusted P-value < 0.05. PGVDA was calculated by assigning the log odds ratio to each variant dosage and then computing a weighted average at the pathway level. Dimensionality reduction was performed via hierarchical clustering based on gene-set overlaps and then PGVDAs with a variance inflation factor (VIF) > 10 were excluded. ML models were evaluated using leave-one-out cross validation. Utilizing the best-performing model, SHAP-based interpretation was applied using two distinct input configurations. Pathway-level interpretation using PGVDA input included stages of PGVDA scaling and ML-based classification, while variant-level interpretation using variant dosage input encompassed stages from odds ratio-based weight assignment to ML-based classification. Using logistic regression model with best performance, key differentiating five PGVDAs and 10 genes within each pathway were identified, suggesting that pathway-level variant aggregation enables accurate and interpretable classification of these two neuromuscular diseases. External validation is needed to ensure generalizability across populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.